Top 4 Peptide Researchers of Therapeutic Peptides – Zheng B, Wang X, Guo M, Tzeng C-M

Meet the Research Team — Xiamen University, China

CT

Prof. Chi-Meng Tzeng, Ph.D. Corresponding Author

Full Professor & Executive Director

Translational Medicine Research Center (TMRC) & School of Pharmaceutical Sciences, Xiamen University, China

122+

Publications

2,458+

Citations

30+

Years Research

Prof. Tzeng is one of China's most versatile translational scientists, bridging the gap between bench discovery and clinical application across oncology, immunology, and precision medicine. He earned his Ph.D. from National Tsing-Hua University (Nuclear Science, 1989–1993) and completed postdoctoral training at Stanford University's Departments of Structural Biology and Biochemistry (1994–1999) — an elite scientific pedigree that has shaped his cross-disciplinary approach for three decades.

His laboratory at Xiamen University has pioneered the application of high-throughput screening biochips (HTS), high-content screening (HCS), next-generation sequencing (NGS), and gene-editing platforms to decode biomarkers for diagnostics, drug targets, and cell-based therapies. He serves as Director of the Key Laboratory for Cancer T-Cell Theranostics and Clinical Translation (CTCTCT) and has held leadership positions at Shanghai Biochip, VitaGenomics/GeneCore, and U-Vision Biotech. His research interests span MSC/NK/T cell engineering, neurodegenerative disease, skin immune disorders, and — most recently — the clinical translation of therapeutic peptides.

Translational Medicine Cancer T-Cell Theranostics Precision Medicine Drug Discovery Gene Editing Therapeutic Peptides

BZ

Bingyi Zheng

Researcher — First Author

Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, China

Bingyi Zheng is a pharmaceutical researcher at Xiamen University's Translational Medicine Research Center, where his work sits at the intersection of peptide therapeutics and regenerative medicine. He is the lead author of the 2025 landmark review on therapeutic peptides published in the International Journal of Molecular Sciences (PMCID: PMC12154100), a comprehensive synthesis of discovery methods, synthesis technologies, and clinical applications across metabolic disorders, oncology, and infectious diseases.

Zheng has also co-authored a 2025 study on mesenchymal stem cell (MSC)-derived extracellular vesicles, reflecting a research portfolio focused on next-generation biotherapeutics. His contributions to the peptide review spanned software development, data validation, formal analysis, and the writing of the original manuscript — indicating a hands-on role in both the computational and scientific aspects of the work.

Therapeutic Peptides Stem Cell Biology Extracellular Vesicles Drug Synthesis Clinical Translation

XW

Xueting Wang

Researcher — Co-Author

Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, China

Xueting Wang is a researcher at Xiamen University's Translational Medicine Research Center, contributing to both peptide therapeutics and cellular therapy research. In the 2025 therapeutic peptides review, Wang's role centred on investigation, resources, and data curation — the critical groundwork of assembling, verifying, and organising the scientific evidence base that underpins the study's conclusions.

Wang is also a co-author on the team's parallel 2025 publication examining advances in MSC-derived extracellular vesicles, suggesting a broader research focus encompassing cell-based and peptide-based therapeutic strategies. The dual focus reflects a growing trend in translational pharmacology — recognising that peptide drugs and cell therapies increasingly converge in areas such as personalised cancer vaccines and regenerative medicine.

Peptide Therapeutics Cellular Therapeutics Data Curation Pharmaceutical Sciences

MG

Meizhai Guo

Researcher — Co-Author

Translational Medicine Research Center, School of Pharmaceutical Sciences, Xiamen University, China

Meizhai Guo is a researcher at Xiamen University whose scientific contributions span the full spectrum of next-generation biotherapeutics. On the 2025 therapeutic peptides review, Guo's responsibilities included validation and formal analysis — ensuring the scientific integrity of the data and conclusions presented across discovery, synthesis, and clinical translation sections.

Guo has also taken a lead authorship role on a complementary 2025 paper reviewing cellular therapeutics clinical trials, examining advances, challenges, and future directions in a field that closely intersects with peptide-based medicine. Published in the same journal, that work — co-authored with Zheng, Wang, and Tzeng — demonstrates the team's coordinated effort to map the frontiers of both peptide and cell-based therapeutic strategies simultaneously, positioning the Xiamen TMRC group as a significant voice in translational biopharmaceutics.

Cellular Therapeutics Clinical Trials Validation & Analysis Biopharmaceutics Therapeutic Peptides